YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
Clinical trial NCT06662669 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06662669
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-30
- Primary completion
- 2027-09-30
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.